A Phase I Study of the Combination of Azacitidine, Cyclophosphamide, Vincristine, and Rituximab in Relapsed and Refractory Lymphoma

被引：2
|
作者：
Moss, Jessica J. [1 ]
Howard, Dianna [1 ]
Van Meter, Emily [1 ]
Hayslip, John [1 ]
机构：
[1] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.1624.1624
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：706 / 706
页数：1
相关论文
共 50 条
  • [1] Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma
    Lee, Hun Ju
    Romaguera, Jorge E.
    Feng, Lei
    Desai, Aakash P.
    Zhang, Liang
    Fanale, Michelle
    Samaniego, Felipe
    Hagemeister, Fredrick B.
    Fayad, Luis E.
    Rodriguez, Maria A.
    Medeiros, Jeffrey L.
    Hartig, Kimberly
    Nomie, Krystle
    Ahmed, Makhdum
    Badillo, Maria
    Ye, Haige
    Oki, Yasuhiro
    Lin, Pei
    Nastoupil, Loretta
    Westin, Jason
    Wang, Michael
    ONCOLOGIST, 2017, 22 (05): : 549 - 553
  • [2] A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Luhua
    Fayad, Luis
    Hagemeister, Fredrick B.
    Neelapu, Sattva
    Samaniego, Felipe
    McLaughlin, Peter
    Samuels, Barry
    Yi, Qing
    Pro, Barbara
    Fanale, Michelle
    Shah, Jatin
    Younes, Anas
    Bell, Neda
    Knight, Robert
    Zeldis, Jerome B.
    Cabanillas, Fernando
    Kwak, Larry
    Romaguera, Jorge
    BLOOD, 2009, 114 (22) : 1064 - 1065
  • [3] A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
    Tuscano, Joseph M.
    Maverakis, Emanual
    Groshen, Susan
    Tsao-Wei, Denice
    Luxardi, Guillaume
    Merleev, Alexander A.
    Beaven, Anne
    DiPersio, John F.
    Popplewell, Leslie
    Chen, Robert
    Kirschbaum, Mark
    Schroeder, Mark A.
    Newman, Edward M.
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7004 - 7013
  • [4] Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma
    Craig, Michael
    Hanna, Wahid T.
    Cabanillas, Fernando
    Chen, Chien-Shing
    Esseltine, Dixie-Lee
    Neuwirth, Rachel
    O'Connor, Owen A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (06) : 920 - 928
  • [5] Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma
    Borchmann, Peter
    Herbrecht, Raoul
    Wilhelm, Martin
    Morschhauser, Franck
    Hess, Georg
    Cernohous, Paul
    Veals, Susan A.
    Singer, Jack W.
    Engert, Andreas
    LEUKEMIA & LYMPHOMA, 2011, 52 (04) : 620 - 628
  • [6] Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
    Kelly, Kevin R.
    Friedberg, Jonathan W.
    Park, Steven I.
    McDonagh, Kevin
    Hayslip, John
    Persky, Daniel
    Ruan, Jia
    Puvvada, Soham
    Rosen, Peter
    Iyer, Swaminathan Padmanabhan
    Stefanovic, Alexandra
    Bernstein, Steven H.
    Weitman, Steven
    Karnad, Anand
    Monohan, Gregory
    VanderWalde, Ari
    Mena, Raul
    Schmelz, Monika
    Spier, Catherine
    Groshen, Susan
    Venkatakrishnan, Karthik
    Zhou, Xiaofei
    Sheldon-Waniga, Emily
    Leonard, E. Jane
    Mahadevan, Daruka
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6150 - 6159
  • [7] Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study
    Craig, Michael
    Hanna, Wahid T.
    Cabanillas, Fernando
    Chen, Chien-Shing
    Parasuraman, Sudha
    Neuwirth, Rachel
    O'Connor, Owen A.
    BLOOD, 2010, 116 (21) : 1153 - 1154
  • [8] Lenalidomide in combination with rituximab is effective with manageable toxicity in a phase I/II study in relapsed/refractory mantle cell lymphoma
    Wang, M.
    Fayad, L.
    Hagemeister, F.
    Neelapu, S.
    Samuels, B.
    Samanigo, F.
    Pro, B.
    Yi, Q.
    Bell, N.
    Byrne, C.
    Weaver, P.
    Hartig, K.
    Knight, R.
    Zeldis, J.
    Kwak, L.
    Romaguera, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 174 - 174
  • [9] Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL)
    Romaguera, Jorge E.
    Fanale, Michelle A.
    Samaniego, Felipe
    Fayad, Luis E.
    Hagemeister, Fredrick B.
    McLaughlin, Peter
    Rodriguez, Maria Alma
    Weaver, Pam
    Hartig, Kim
    Badillo, Maria
    Kwak, Larry W.
    Younes, Anas
    Pro, Barbara
    Wang, Michael
    BLOOD, 2013, 122 (21)
  • [10] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
12345